A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients
Year: 2026
Type: article
Abstract: Smoldering multiple myeloma (SMM) is a precursor to active multiple myeloma (MM) characterized by a higher plasma cell burden than monoclonal gammopathy of undetermined significance (MGUS) but without evidence of the end-organ damage that defines MM [ 1 , 2 ]. Current SMM guidelines advocate for close observation for progression to symptomatic progression to MM, with some studies suggesting the benefit of early intervention for patients with a high risk (HR) of progression [ 3 ]. Current methods to prognosticate SMM outcomes, including the Mayo 2/20/20 model, rely primarily on methods of tumor-burden assessment to assign risk scores and identify which patients are at HR of progression [ 4 ]. As SMM is an asymptomatic condition, great consideration must be made for who to select for systemic therapy, as many SMM patients may never progress to MM in their lifetimes [ 5 ].
Source: Blood Cancer Journal
Authors: Ross S. Firestone, Anish K. Simhal, Theresia Akhlaghi, Jung Hun Oh, Devin McAvoy, Kylee H. Maclachlan, Juan-Jose Garces, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Neha Korde, Carlyn R. Tan, Sridevi Rajeeve, Hamza Hashmi, Alexander M. Lesokhin, Kinga Hosszu, Francesco Maura, Joseph O. Deasy, Saad Z. Usmani, Malin Hultcrantz
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
Funders: Conquer Cancer Foundation, Breast Cancer Research Foundation, Amgen, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Sanofi, Celgene, Memorial Sloan-Kettering Cancer Center, BeiGene, SkylineDx, Springworks Therapeutics, Russian Science Foundation, National Institutes of Health, Takeda Oncology, Pharmacyclics, Legend Biotech, National Cancer Institute, Janssen Biotech, Daiichi Sankyo Europe
OpenAlex ID: W7159810557